NCT07197164 - Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

February 28, 2027

Conditions

COVID - 19Renal TransplantSARS CoV 2 Infection

Interventions

DRUG

Remdesivir (RDV)

Participants will receive their first dose of remdesivir also within the 24 (+/-12) hours prior to going to the operating room. Remdesivir doses will be 200 mg on day 1, followed by 100 mg daily from days 2 to 10, for a total of 10 days.

Trial Locations (1)

08916

RECRUITING

Hospital Universitari Germans Trias i Pujol, Badalona